NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026
Rhea-AI Summary
NeurAxis (NYSE American: NRXS) will report summarized financial results for the first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026 before market open. The company also scheduled a conference call the same day at 9:00 AM ET to review results, with webcast and replay details provided.
Dial-in numbers, webcast link, and replay access code are available for investors and analysts to listen live or access the replay.
Positive
- None.
Negative
- None.
News Market Reaction – NRXS
In the May 5 session, NRXS gained 4.70%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.3% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Earnings results | Positive | +2.4% | Reported strong 4Q25 and FY2025 revenue growth with key commercial wins. |
| Mar 12 | Earnings call notice | Neutral | +0.5% | Announced timing and access details for Q4 and FY2025 results call. |
| Nov 11 | Earnings results | Positive | -5.9% | Q3 2025 revenues rose 22% with multiple FDA clearances and coverage gains. |
| Aug 12 | Earnings results | Positive | +2.5% | Q2 2025 revenues grew 46% with operating loss improvement and cash support. |
| May 12 | Earnings results | Positive | +16.0% | Q1 2025 revenues increased 39% and covered lives expanded to 51 million. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related news has usually led to modestly positive one-day moves, with one notable selloff despite strong fundamentals.
Recent earnings and financial updates for NeurAxis have highlighted consistent revenue growth and recurring milestones. Q1, Q2, Q3, and Q4 2025 results all emphasized double‑digit revenue gains and commercial progress, with one-day moves ranging from about flat to +16% and one decline of roughly -5.86%. The March 19, 2026 full-year 2025 report also showed strong growth and a 2.43% gain. Today’s Q1 2026 call announcement fits into this regular cadence of earnings communication.
Key Terms
neuromodulation therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its first quarter 2026, for the period ended March 31, 2026, on Tuesday, May 12, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, May 12, 2026, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Tuesday, May 12, 2026, at 9:00am ET
Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060
Webcast: https://app.webinar.net/892nzbBzqeJ
Replay: Toll Free: 1-855-669-6958 (U.S. and Canada toll-free) International: 1-412-317-0088
Replay access code: 5040620
Webcast: https://app.webinar.net/892nzbBzqeJ
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.
For more information, please visit http://neuraxis.com.
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
